Provided by Tiger Trade Technology Pte. Ltd.

Merck

149.08
+1.320.89%
Volume:4.33M
Turnover:647.11M
Market Cap:367.79B
PE:117.12
High:151.68
Open:150.23
Low:148.55
Close:147.76
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.55
T/O Rate:0.18%
Dividend:3.32
Dividend Rate:2.23%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.77
PE(LYR):20.48

Loading ...

Merck (MRK) Stock Could Be 11% Undervalued After June Pipeline Wins

Simply Wall St.
·
Jun 23

Spanish stocks - Factors to watch on June 23

Reuters
·
Jun 23

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 23

Merck's bowel disease drug meets main goal in late-stage trial

Reuters
·
Jun 22

Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study

Dow Jones
·
Jun 22

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

TIPRANKS
·
Jun 22

Merck says Phase 3 trial shows tulisokibart meets primary endpoint in ulcerative colitis study

Reuters
·
Jun 22

Merck & Co - No Safety Concerns Identified in Phase 3 Atlas-Uc Study of Tulisokibart

THOMSON REUTERS
·
Jun 22

Merck & Co - Tulisokibart First Anti-Tl1a Antibody to Show Clinical Remission at 12 Weeks in Phase 3 Uc Trial

THOMSON REUTERS
·
Jun 22

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 Atlas-Uc Induction-Only Study in Patients With Moderately to Severely Active Ulcerative Colitis (Uc)

THOMSON REUTERS
·
Jun 22

Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating

MT Newswires Live
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

This Investment Pro Is Leaning Into Risk -- Barron's

Dow Jones
·
Jun 20

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 19

Movement Alert|Merck Falls 3.01% in Regular Trading, Trading at $111.89

Market Focus
·
Jun 18

Merck says FDA approves additional indication for Capvaxive

TIPRANKS
·
Jun 18

FDA approves Merck CAPVAXIVE use in at-risk children, adolescents aged 2-17

Reuters
·
Jun 18

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Reuters
·
Jun 18

This Investment Pro Is Leaning Into Risk. Why He Likes Defense, Ag Tech, and Infrastructure. -- Barrons.com

Dow Jones
·
Jun 18